Kiniksa Pharmaceuticals International, plc (KNSA)
NASDAQ · Healthcare
Kiniksa Pharmaceuticals International, plc Shareholder Equity 2021–2025
Kiniksa Pharmaceuticals International, plc annual shareholder equity history from 2021 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Kiniksa Pharmaceuticals International, plc shareholder equity as of December 31, 2025: 567.6M, a 29.46% increase year-over-year.
- Kiniksa Pharmaceuticals International, plc shareholder equity for 2025 were 567.6M, a 29.46% increase from 2024.
- Kiniksa Pharmaceuticals International, plc shareholder equity for 2024 were 438.4M, a 0.09% decrease from 2023.
- Kiniksa Pharmaceuticals International, plc shareholder equity for 2023 were 438.8M, a 10.78% increase from 2022.
- Kiniksa Pharmaceuticals International, plc shareholder equity for 2022 were 396.1M.
Shareholder Equity
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| Kiniksa Pharmaceuticals International, plc Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $568 |
| 2024 | $438 |
| 2023 | $439 |
| 2022 | $396 |
| 2021 | $185 |
Kiniksa Pharmaceuticals International, plc Shareholder Equity — FAQ
Kiniksa Pharmaceuticals International, plc (KNSA) shareholder equity over the last 5 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see KNSA's shareholder equity history?
The chart and table above show Kiniksa Pharmaceuticals International, plc's shareholder equity by year and by quarter, including the growth rate.